Publication | Closed Access

Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation

Cell TherapyTransplantationMarrow TransplantationPromising TherapyStem Cell TransplantationImmunologyHematologyAutoimmunityGraft SurvivalCell TransplantationBlood TransplantationImmunotherapyMedicineRadiation OncologyRelapsed/refractory B-allHealth Sciences